© Reuters. FILE PHOTO: A logo of the British chemist chain, Boots, is seen in central London October 3, 2005.
(Reuters) – Walgreens Boots Alliance (NASDAQ:) Inc has begun a strategic review of its U.K.-based Boots business, Chief Executive Officer Rosalind Brewer said on Tuesday, as the second largest U.S. pharmacy chain tries to renew its focus on U.S. healthcare.
The Boots business has over 2,200 stores across the UK, which include pharmacies, health and beauty stores, among others, according to the chain’s website.
“This review is very much in line with our renewed priorities and strategic direction. In particular, our increased focus on U.S. healthcare. While the process is at an exploratory stage, we do expect to move quickly,” Brewer said at the J.P Morgan Healthcare Conference.
The review comes at a time when the company, which was formed in 2014 after the acquisition of stake in Alliance Boots by Walgreens, moves beyond its drugstores with its investments in two smaller healthcare providers, CareCentrix and VillageMD.
Late last year, Walgreens also launched its Walgreens Health unit to provide pharmacy and primary care services in stores, at home, or at a doctor’s office and via mobile app.
Boots UK comparable pharmacy sales increased 8.8% in the quarter ended November due to increased footfalls.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.